-
Product Insights
NewNet Present Value Model: EQRx Inc’s Lerociclib
Empower your strategies with our Net Present Value Model: EQRx Inc's Lerociclib report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: EQRx Inc’s Nofazinlimab
Empower your strategies with our Net Present Value Model: EQRx Inc's Nofazinlimab report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Werewolf Therapeutics Inc’s WTX-124
Empower your strategies with our Net Present Value Model: Werewolf Therapeutics Inc's WTX-124 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lerociclib in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lerociclib in Metastatic Breast Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lerociclib in Metastatic Breast Cancer Drug Details: lerociclib is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lerociclib in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lerociclib in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lerociclib in Non-Small Cell Lung Cancer Drug Details: lerociclib is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lerociclib in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lerociclib in Endometrial Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Lerociclib in Endometrial CancerDrug Details:lerociclib is under development for the treatment of estrogen-receptor...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Colestilan Chloride in Familial Amyloid Neuropathies
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Colestilan Chloride in Familial Amyloid Neuropathies report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Colestilan Chloride in Familial Amyloid Neuropathies Drug Details: Colestilan chloride...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Favezelimab in Gastric Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Favezelimab in Gastric Cancer Drug Details: Favezelimab (MK-4280) is under development for the treatment of...
-
Product Insights
Net Present Value Model: EQ-121
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model EQ-121 Drug Details EQ-121 is under...